NASH Observatory
⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
The Role of Liver Sinusoidal Endothelial Cells
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prognostic value of non-alcoholic fatty liver disease in the elderly patients
Complications, morbidity and mortality of nonalcoholic fatty liver disease.
What can we expect from PPAR agonists in the treatment of NASH?
Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.
Pre-clinical study with Lanifibranor – Prof Gracia-Sancho
Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.
Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease
Flaxseed oil in the context of a weight loss program ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomized double-blind controlled trial
Long-chain omega-3 fatty acids have shown to regulate lipid metabolism and reduce fat accumulation in the liver. Masoumeh Akhlaghi et al. (Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran) investigated the effect of flaxseed oil, as a rich source...
Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.
Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way
Why are NASH patients at increased CV risk & how can PPAR agonists potentially improve outcomes?
Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.